Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
Kintara |
Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies, is reminding stockholders to vote at the upcoming Special Meeting of Stockholders to be held on September 20, 2024 to allow for the completion of its proposed merger with TuHURA Biosciences, Inc. .
Read at finance.yahoo.com
 |
Kintara Therapeutics Fundamental Analysis
We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Kintara Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Kintara Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.
Peers
Kintara Therapeutics Related Equities
| ONCY | Oncolytics Biotech | 1.85 | ||||
| MCRB | Seres Therapeutics | 1.59 | ||||
| SCPH | Scpharmaceuticals | 0.31 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| SLRX | Salarius Pharmaceuticals | 0.00 | ||||
| MIST | Milestone Pharmaceuticals | 0.00 | ||||
| LSTA | Lisata Therapeutics | 0.00 | ||||
| TOVX | Theriva Biologics | 0.85 | ||||
| CLRB | Cellectar Biosciences | 0.88 | ||||
| VCNX | Vaccinex | 1.08 | ||||
| DMAC | DiaMedica Therapeutics | 1.30 | ||||
| GOVX | GeoVax Labs | 2.55 | ||||
| BOLT | Bolt Biotherapeutics | 2.83 | ||||
| SABS | SAB Biotherapeutics | 2.94 | ||||
| DYAI | Dyadic International | 8.59 | ||||
| FBRX | Forte Biosciences | 18.10 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |